APA (7th ed.) Citation

P, S., L, F., JR, W., R, N., LE, F., MA, R., . . . SS, N. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: Phase II trial. Nature communications, 16(1), 7300. https://doi.org/10.1038/s41467-025-62509-z

Chicago Style (17th ed.) Citation

P, Strati, et al. "Frontline Acalabrutinib, Lenalidomide and Rituximab for Advanced Stage Follicular Lymphoma with High Tumor Burden: Phase II Trial." Nature Communications 16, no. 1 (2025): 7300. https://doi.org/10.1038/s41467-025-62509-z.

MLA (9th ed.) Citation

P, Strati, et al. "Frontline Acalabrutinib, Lenalidomide and Rituximab for Advanced Stage Follicular Lymphoma with High Tumor Burden: Phase II Trial." Nature Communications, vol. 16, no. 1, 2025, p. 7300, https://doi.org/10.1038/s41467-025-62509-z.